Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Niagen Bioscience ( (NAGE) ) just unveiled an update.
Niagen Bioscience reported on March 4, 2026 that 2025 net sales rose 30% year over year to $129.4 million, driven by strong Tru Niagen and Niagen ingredient demand, while gross margin improved to 64.3%. Net income more than doubled to $17.4 million, adjusted EBITDA climbed 139% to $20.4 million and the company ended 2025 with $64.8 million in cash and no debt, supporting its 2026 outlook for 10–15% net sales growth excluding the recently divested reference standards segment.
Fourth-quarter 2025 net sales grew 16% to $33.8 million on robust e-commerce performance, although net income fell to $4.1 million due to higher operating expenses and the absence of prior-year one-off benefits. Recent moves—including the February 2026 sale of its analytical reference standards segment, a January 2026 HSA/FSA purchase partnership for Tru Niagen, the December 2025 acquisition of core NR patents, and launches and clinical data in 2025—underscore a strategic pivot toward higher-margin consumer health and IP-driven growth, with implications for stronger brand positioning and expanded monetization opportunities.
The most recent analyst rating on (NAGE) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.
The score is driven primarily by strong financial performance (profitability, low leverage, and accelerating cash flow) and a solid earnings update with raised growth guidance. Offsetting factors include weak technical trend signals (below major moving averages and negative MACD) and a moderately elevated P/E with no dividend yield data to support valuation.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. is a NASDAQ-listed health and wellness company focused on nicotinamide riboside (NR) and NAD+ science, commercialized primarily through its Tru Niagen-branded dietary supplements and Niagen ingredient sales. The company targets consumer health, nutricosmetics and potential future pharmaceutical applications, leveraging proprietary IP around NR and related salt forms.
Average Trading Volume: 857,856
Technical Sentiment Signal: Sell
Current Market Cap: $388.7M
Find detailed analytics on NAGE stock on TipRanks’ Stock Analysis page.